Meiji Seika Pharma's Nacubactam to be Highlighted in ESCMID Global 2026 Presentations
Meiji Seika Pharma Co., Ltd. is set to present ten studies on its novel β-lactamase inhibitor nacubactam at the ESCMID Global 2026 conference. The presentations will include results from the Integral-2 Phase III clinical trial, which focuses on infections caused by carbapenem-resistant Enterobacterales (CRE). Carbapenem-resistant bacteria are a significant global threat, as carbapenems are often the last-resort treatment for severe infections. Meiji Seika Pharma has submitted an application for manufacturing and marketing approval of nacubactam in Japan, aiming to contribute to global efforts against antimicrobial resistance (AMR). The presentations will cover various aspects of nacubactam's efficacy and safety, including its combination with existing β-lactam antibiotics like cefepime and aztreonam.